Clinical Trials

Study Title:
A Phase 2a Study with Safety Run-in to Evaluate the Safety, Tolerability, and Preliminary Efficacy of FF-10832 Monotherapy or in Combination with Pembrolizumab in Patients with Advanced Solid Tumors

For more information about the trial above please contact the study team:

Medical University of South Carolina
Principal Investigator, Theodore Gourdin, at gourdith@musc.edu.
Study Coordinator, Holly Boggan, at bogganhl@musc.edu, or please call +1 843-792-8068.

Trial opened at the following institutions: Medical University of South Carolina